Works matching IS 01145916 AND DT 2023 AND VI 46 AND IP 2

Results: 8

Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 157, doi. 10.1007/s40264-022-01263-3

By:

Johannes, Catherine B.;
Beachler, Daniel C.;
Layton, J. Bradley;
Danysh, Heather E.;
Ziemiecki, Ryan;
Arana, Alejandro;
Dinh, Jade;
Li, Ling;
Calingaert, Brian;
Pladevall-Vila, Manel;
Hunt, Phillip R.;
Chen, Hungta;
Karlsson, Cecilia;
Johnsson, Kristina;
Gilsenan, Alicia

Publication type:

Article

Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 175, doi. 10.1007/s40264-022-01262-4

By:

Danysh, Heather E.;
Johannes, Catherine B.;
Beachler, Daniel C.;
Layton, J. Bradley;
Ziemiecki, Ryan;
Arana, Alejandro;
Dinh, Jade;
Li, Ling;
Calingaert, Brian;
Pladevall-Vila, Manel;
Hunt, Phillip R.;
Chen, Hungta;
Karlsson, Cecilia;
Johnsson, Kristina;
Gilsenan, Alicia

Publication type:

Article

Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 209, doi. 10.1007/s40264-022-01261-5

By:

Chomistek, Andrea K.;
Phiri, Kelesitse;
Doherty, Michael C.;
Calderbank, Jenna F.;
Chiuve, Stephanie E.;
McIlroy, Brenda Hinman;
Snabes, Michael C.;
Enger, Cheryl;
Seeger, John D.

Publication type:

Article

Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 195, doi. 10.1007/s40264-022-01260-6

By:

Layton, J. Bradley;
Forns, Joan;
McQuay, Lisa J.;
Danysh, Heather E.;
Dempsey, Colleen;
Anthony, Mary S.;
Turner, Mary Ellen

Publication type:

Article

Signals of Adverse Drug Reactions Communicated by Pharmacovigilance Stakeholders: A Scoping Review of the Global Literature.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 109, doi. 10.1007/s40264-022-01258-0

By:

Sartori, Daniele;
Aronson, Jeffrey K.;
Norén, G. Niklas;
Onakpoya, Igho J.

Publication type:

Article

Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 129, doi. 10.1007/s40264-022-01255-3

By:

Suzuki, Ayako;
Tillmann, Hans;
Williams, James;
Hauser, Ronald G.;
Frund, Julie;
Suzuki, Mizuki;
Prior, Fred;
Aithal, Guruprasad P.;
Lucena, M. Isabel;
Andrade, Raúl J.;
Tong, Weida;
Hunt, Christine M.

Publication type:

Article

Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 121, doi. 10.1007/s40264-022-01234-8

By:

Fauvelle, Khristina;
Bigna, Jean Joel

Publication type:

Article

The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.

Published in:

Drug Safety, 2023, v. 46, n. 2, p. 145, doi. 10.1007/s40264-022-01256-2

By:

Diak, Ida-Lina;
Swank, Kimberley;
McCartan, Kate;
Beganovic, Maya;
Kidd, James;
Gada, Neha;
Kapoor, Rachna;
Wolf, Lisa;
Kangas, Laura;
Wyeth, Jo;
Salvatore, Toni;
Fanari, Melina;
LeBoeuf, Andrew A.;
Mishra, Poonam;
Blum, Michael D.;
Dal Pan, Gerald

Publication type:

Article